Quality of life with trimetazidine

Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical benefits provided by trimetazidine on one hand, and of its optimal tolerability profile on the other. Benefits of trimetazidine administration include symptom relief, particularly reduction of episodes of angina and dyspnea with a resulting improvement in exercise tolerance. The clinical effectiveness of trimetazidine can alone explain its impact on quality of life in a disease, such as ischemic cardiomyopathy, where poor quality of life is strongly related to the limitation of daily living activities imposed by symptoms.